KBC Group
NTLA icon

KBC Group’s Intellia Therapeutics NTLA Stock Holding History

KBC Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$47K Hold
3,928
– – ﹤0.01% 1738
2026
Q2 		$66K Hold
3,928
– – ﹤0.01% 1615
2026
Q1 		$50K Sell
3,928
-2,165
-36% -$27.6K ﹤0.01% 1652
2025
Q4 		$55K Hold
6,093
– – ﹤0.01% 1608
2025
Q3 		$105K Hold
6,093
– – ﹤0.01% 1226
2025
Q2 		$57K Hold
6,093
– – ﹤0.01% 1546
2025
Q1 		$43K Hold
6,093
– – ﹤0.01% 1818
2024
Q4 		$71K Buy
6,093
+2,340
+62% +$36.5K ﹤0.01% 1727
2024
Q3 		$77K Buy
3,753
+1,020
+37% +$23.5K ﹤0.01% 1459
2024
Q2 		$61K Buy
2,733
+940
+52% +$22.4K ﹤0.01% 1499
2024
Q1 		$49K Hold
1,793
– – ﹤0.01% 1572
2023
Q4 		$55K Hold
1,793
– – ﹤0.01% 1461
2023
Q3 		$57K Buy
+1,793
New +$69.6K ﹤0.01% 1337
2020
Q4 		– Sell
-1,020
Closed -$20K – 1277
2020
Q3 		$20K Hold
1,020
– – ﹤0.01% 1213
2020
Q2 		$21K Hold
1,020
– – ﹤0.01% 1248
2020
Q1 		$12K Hold
1,020
– – ﹤0.01% 1266
2019
Q4 		$15K Sell
1,020
-2,940
-74% -$40.9K ﹤0.01% 1469
2019
Q3 		$53K Buy
3,960
+3,440
+662% +$54.8K ﹤0.01% 1384
2019
Q2 		$9K Hold
520
– – ﹤0.01% 1438
2019
Q1 		$9K Buy
520
+260
+100% +$3.88K ﹤0.01% 1397
2018
Q4 		$4K Sell
260
-265
-50% -$4.93K ﹤0.01% 1305
2018
Q3 		$14K Hold
525
– – ﹤0.01% 1375
2018
Q2 		$14K Hold
525
– – ﹤0.01% 1274
2018
Q1 		$11K Hold
525
– – ﹤0.01% 1262
2017
Q4 		$10K Buy
+525
New +$12.1K ﹤0.01% 1247

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Contrarius Group Holdings
Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

KBC Group's NTLA Position: Q3 2026 in Review

KBC Group held its Intellia Therapeutics (NTLA) position steady in Q3 2026 at 3,928 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #1738.

KBC Group first reported a position in NTLA in Q4 2017 and has held it in 25 quarters since. The position peaked at $105K in Q3 2025. 156 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • KBC Group held 3,928 shares of Intellia Therapeutics worth $47K as of Q3 2026.
  • KBC Group left its Intellia Therapeutics share count unchanged in Q3 2026.
  • Intellia Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1738 holding.
  • KBC Group first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 25 quarters since.
  • KBC Group's Intellia Therapeutics position peaked at $105K in Q3 2025.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.